Loading...

Petlife Pharmaceuticals, Inc.

PTLF•PNK
HealthcareDrug Manufacturers - Specialty & Generic
$0.00
$0.00(0.00%)

Petlife Pharmaceuticals, Inc. (PTLF) Stock Overview

Explore Petlife Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for PTLFStats details for PTLF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for PTLFAnalyst Recommendations details for PTLF are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor. In addition, the company develops edible dog and cat treats. Petlife Pharmaceuticals, Inc. is based in Los Angeles, California.

CEO

Mr. Sebastian Serrell-Watts

Employees

1

Headquarters

8033 Sunset Boulevard, Los Angeles, CA

Founded

2008

Frequently Asked Questions